Daniel Morgensztern

Trials

Studies that name Daniel Morgensztern as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:24 UTC. Open this list on ClinicalTrials.gov

• Ph3
  NCT06632327 · Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

  Alliance for Clinical Trials in Oncology · active not recruiting · Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 · study chair
• Ph1
  NCT05062980 · Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

  Genprex, Inc. · terminated · Non Small Cell Lung Cancer · principal investigator
• Ph1
  NCT05049863 · Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

  Washington University School of Medicine · terminated · Small-cell Lung Cancer, Small Cell Lung Carcinoma · principal investigator
• Ph2
  NCT05007769 · Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

  Washington University School of Medicine · withdrawn · Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC · principal investigator
• Ph2
  NCT04791839 · Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

  Washington University School of Medicine · active not recruiting · Non Small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer · principal investigator
• Ph2
  NCT04373369 · Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

  Washington University School of Medicine · terminated · Extensive-stage Small Cell Lung Cancer · principal investigator
• Ph2
  NCT03689855 · Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

  Washington University School of Medicine · completed · Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC · principal investigator
• N/A
  NCT03553550 · Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

  Addario Lung Cancer Medical Institute · terminated · Non Small Cell Lung Cancer · principal investigator
• Ph1/Ph2
  NCT02439450 · A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

  Heat Biologics · completed · Non-small Cell Lung Cancer · principal investigator
• N/A
  NCT02431169 · Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression

  Washington University School of Medicine · terminated · Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer · principal investigator
• Ph1
  NCT02342353 · Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

  Washington University School of Medicine · terminated · Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung · principal investigator
• Ph2
  NCT02193152 · Pazopanib in Molecularly Selected Patients With Advanced NSCLC

  Washington University School of Medicine · terminated · Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer · principal investigator
• Ph2
  NCT00442507 · Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

  Washington University School of Medicine · terminated · Esophageal Neoplasms, Esophageal Diseases · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 22:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.